Prior Cancer and Survival in Patients With Esophageal Squamous Cell Carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
5557 patients (mean [SD] age, 64.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
A latency of 5 or more years was also associated with reduced OS (HR, 1.27; 95% CI, 1.03-1.57; P = .02). [CONCLUSIONS AND RELEVANCE] In this nationwide Korean cohort study, prior cancer was an independent adverse prognostic factor in ESCC, with stomach, head and neck, and lung cancers associated with the poorest outcomes.
[IMPORTANCE] Esophageal squamous cell carcinoma (ESCC) is highly prevalent in Asian populations and carries a poor prognosis.
- p-value P < .001
- p-value P = .02
- 95% CI 2.50-4.92
- 연구 설계 cohort study
APA
Yu S, Hong JT, et al. (2026). Prior Cancer and Survival in Patients With Esophageal Squamous Cell Carcinoma.. JAMA network open, 9(2), e2560193. https://doi.org/10.1001/jamanetworkopen.2025.60193
MLA
Yu S, et al.. "Prior Cancer and Survival in Patients With Esophageal Squamous Cell Carcinoma.." JAMA network open, vol. 9, no. 2, 2026, pp. e2560193.
PMID
41719041 ↗
Abstract 한글 요약
[IMPORTANCE] Esophageal squamous cell carcinoma (ESCC) is highly prevalent in Asian populations and carries a poor prognosis. With growing numbers of cancer survivors, the prognostic impact of prior cancer in ESCC remains unclear. Most existing data are derived from Western cohorts dominated by adenocarcinoma, limiting generalizability to Asian populations.
[OBJECTIVE] To evaluate whether prior cancer is associated with overall survival (OS) and esophageal cancer-specific mortality (ECSM) in a nationwide Korean ESCC cohort.
[DESIGN, SETTING, AND PARTICIPANTS] A retrospective cohort study of patients with newly diagnosed ESCC across 19 tertiary hospitals in Korea from 2005 to 2017 was conducted. Follow-up was completed in 2017. Data were reanalyzed in August 2025. Exclusion criteria were nonsquamous histology (including adenocarcinoma), diagnosis of esophageal cancer within 6 months of a prior cancer, multiple prior cancers, and hematologic cancers.
[EXPOSURES] History of cancer before the diagnosis of ESCC, classified by cancer type and latency (≤5 years vs >5 years).
[MAIN OUTCOMES AND MEASURES] The primary outcome was OS, and the secondary outcome was esophageal cancer-specific mortality (ECSM). Hazard ratios (HRs) and cause-specific hazard ratios (CSHRs) were estimated after adjustment for clinicopathologic and treatment variables. Propensity score-adjusted Cox regression and competing risk regression models were used. Subgroup analyses were conducted by prior cancer type and latency period.
[RESULTS] Of the 5557 patients (mean [SD] age, 64.7 [8.9] years; 5168 [93.0%] male), 368 (6.6%) had a prior cancer and were older and more often diagnosed at an earlier stage than those without prior cancer. Patients with a prior cancer had significantly poorer outcomes, with a median OS of 3.58 (95% CI, 2.50-4.92) vs 4.25 (95% CI, 3.83-4.58) years and a 3-year ECSM of 8.35% (95% CI, 4.42%-12.29%) vs 4.98% (95% CI, 4.17%-5.78%) compared with those without a prior cancer. Prior cancer was independently associated with worse OS (HR, 1.25; 95% CI, 1.07-1.47) and ECSM (CSHR, 1.89; 95% CI, 1.09-3.29). Among prior cancer types, patients with a history of stomach, head and neck, or lung cancer demonstrated poorer OS (HR, 1.63; 95% CI, 1.24-2.15; P < .001). A latency of 5 or more years was also associated with reduced OS (HR, 1.27; 95% CI, 1.03-1.57; P = .02).
[CONCLUSIONS AND RELEVANCE] In this nationwide Korean cohort study, prior cancer was an independent adverse prognostic factor in ESCC, with stomach, head and neck, and lung cancers associated with the poorest outcomes.
[OBJECTIVE] To evaluate whether prior cancer is associated with overall survival (OS) and esophageal cancer-specific mortality (ECSM) in a nationwide Korean ESCC cohort.
[DESIGN, SETTING, AND PARTICIPANTS] A retrospective cohort study of patients with newly diagnosed ESCC across 19 tertiary hospitals in Korea from 2005 to 2017 was conducted. Follow-up was completed in 2017. Data were reanalyzed in August 2025. Exclusion criteria were nonsquamous histology (including adenocarcinoma), diagnosis of esophageal cancer within 6 months of a prior cancer, multiple prior cancers, and hematologic cancers.
[EXPOSURES] History of cancer before the diagnosis of ESCC, classified by cancer type and latency (≤5 years vs >5 years).
[MAIN OUTCOMES AND MEASURES] The primary outcome was OS, and the secondary outcome was esophageal cancer-specific mortality (ECSM). Hazard ratios (HRs) and cause-specific hazard ratios (CSHRs) were estimated after adjustment for clinicopathologic and treatment variables. Propensity score-adjusted Cox regression and competing risk regression models were used. Subgroup analyses were conducted by prior cancer type and latency period.
[RESULTS] Of the 5557 patients (mean [SD] age, 64.7 [8.9] years; 5168 [93.0%] male), 368 (6.6%) had a prior cancer and were older and more often diagnosed at an earlier stage than those without prior cancer. Patients with a prior cancer had significantly poorer outcomes, with a median OS of 3.58 (95% CI, 2.50-4.92) vs 4.25 (95% CI, 3.83-4.58) years and a 3-year ECSM of 8.35% (95% CI, 4.42%-12.29%) vs 4.98% (95% CI, 4.17%-5.78%) compared with those without a prior cancer. Prior cancer was independently associated with worse OS (HR, 1.25; 95% CI, 1.07-1.47) and ECSM (CSHR, 1.89; 95% CI, 1.09-3.29). Among prior cancer types, patients with a history of stomach, head and neck, or lung cancer demonstrated poorer OS (HR, 1.63; 95% CI, 1.24-2.15; P < .001). A latency of 5 or more years was also associated with reduced OS (HR, 1.27; 95% CI, 1.03-1.57; P = .02).
[CONCLUSIONS AND RELEVANCE] In this nationwide Korean cohort study, prior cancer was an independent adverse prognostic factor in ESCC, with stomach, head and neck, and lung cancers associated with the poorest outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Evaluation of Chemotherapy Efficacy in Primary Gastric Diffuse Large B-cell Lymphoma on a Point-based Scoring System: A Multicenter Study.
- PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer.
- Integrative Analysis of Cytotoxic Lymphocytes-Mediated Tumour Killing Related Genes Reveals LDHA as a Novel Glioblastoma Therapeutic Target.
- A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies.
- Tumor-Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.